Earnings call transcript: Valmet's Q2 2025 sees stock surge 10.7% amid strategic shifts

Valmet's Q2 2025 results spurred a 10.7% stock surge, reflecting investor confidence despite mixed financials. The company reported strong 21% organic order growth to €1.5 billion and a 20% increase in its backlog to €4.7 billion, providing solid future visibility. While net sales declined to €1.2 billion and operating cash flow decreased, Valmet's comparable EBITDA margin improved to 11.5%. The positive sentiment is largely driven by the launch of its new 'Lead the Way' strategy and operating model, targeting €80 million in annual cost savings by 2026, as Valmet reaffirms its full-year 2025 guidance for flat net sales and EBITDA, signaling a strategic pivot towards long-term efficiency and growth.

Analysis

Valmet's Q2 2025 results present a dichotomy between robust forward-looking indicators and current operational weaknesses, with the market clearly favoring the former as evidenced by a 10.7% stock price increase. The company's strategic pivot, encapsulated by its new "Lead the Way" strategy and operating model, has bolstered investor confidence. This optimism is underpinned by a significant 21% organic growth in orders received, reaching €1,500 million, and a 20% year-over-year expansion of the order backlog to a solid €4,700 million. However, these strengths are juxtaposed with a decline in net sales to €1,200 million and a decrease in operating cash flow to €79 million. Profitability metrics were mixed; while the comparable EBITDA margin improved to 11.5%, this was largely due to a favorable sales mix tilted towards the high-performing Process Performance Solutions segment (17.8% margin), masking weakness in the larger Biomaterial Solutions and Services segment whose margin stood at 10%. Management's reaffirmation of flat full-year guidance, despite the sales decline and a cautious outlook for its services business, signals strong confidence in the backlog conversion and the anticipated benefits of its restructuring, which targets €80 million in annual cost savings.

Key Decisions for Investors

• Investors should weigh the strong 21% order growth and €4.7 billion backlog against the current decline in net sales, as successful execution of the new strategy and cost-saving program could unlock significant value.
• It is critical to monitor the profitability of the new Biomaterial Solutions and Services segment, as its 10% EBITA margin is substantially below the 2030 target of 14% and its outlook is softening.
• Given the reaffirmed guidance and positive momentum, investors might consider the current valuation, but should watch for confirmation of revenue conversion from the backlog and the materialization of cost savings in the second half of 2025.
• Note the cautious management commentary on biomaterial services, particularly regarding US tariffs and a slowdown in transactional orders, which presents a key short-term risk to the company's most profitable business lines.